首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

2103005

全EXOME定序市場：策略性洞察與預測（2026-2035 年）

Whole Exome Sequencing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年07月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2026 年，全球EXOME定序市場規模將達到 38.3 億美元，到 2035 年將達到 89.6 億美元，年複合成長率為 9.9%。

全EXOME定序(WES) 分析人類基因組的蛋白質轉錄區，這些區域約佔整個基因組的 1-2%，能夠捕捉大多數已知的致病突變。與全基因測序相比，WES 提供了一種經濟高效且具有臨床應用價值的方法，可用於識別與遺傳疾病、癌症、生殖健康和藥物基因體學相關的致病突變。次世代定序(NGS)、長讀長定定序、人工智慧 (AI) 驅動的突變解讀、基於雲端的生物資訊學以及自動化實驗室工作流程的不斷進步，正在拓展 WES 在臨床診斷和生物醫學研究中的應用。

市場促進因素

精準醫療的廣泛應用

醫療保健系統越來越依賴基因組資訊來實現個人化診斷和治療。全EXOME定序使臨床醫生能夠識別具有臨床應用價值的基因變異，從而有助於制定針對多種疾病的個人化治療策略。

罕見疾病診斷範圍擴大

由於傳統診斷方法往往無法辨識潛在的遺傳病因，因此罕見疾病計畫持續推動全外顯子定序（WES）的應用。全EXOME定序能夠同時檢測數千個臨床相關基因中的致病突變，從而顯著提高診斷準確性。

癌症基因檢測需求不斷成長

癌症治療的管理越來越依賴全面的分子特徵分析。全EXOME定序有助於識別體細胞突變、治療生物標記、抗藥性機制以及支撐精準癌症治療和標靶治療的分子標靶。

國家基因組舉措

世界各國政府持續投資基因組醫學計畫和定序基礎設施，以改善公眾健康、加速研究並擴大精準醫療的應用。這些努力正在推動全外EXOME定序在醫療保健系統中的普及。

市場限制因素

定序基礎設施高成本

雖然定序成本持續下降，但檢查室仍需要在定序設備、運算基礎設施和專業人員方面進行大量投資。

解讀突變的複雜性

基因組突變的臨床解讀仍是一項具有挑戰性的任務。這是因為許多檢測到的突變需要經過廣泛的生物資訊分析、臨床檢驗和專家審查，才能用於患者管理。

監管和資料隱私挑戰

醫療機構必須遵守不斷發展的法律規範，該框架規範基因組檢測、患者隱私、檢查室認證和基因組數據的安全管理。

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
市場規模表現分析
市場預測分析
全EXOME定序的臨床效用
基於EXOME的基因組檢測的發展
基因組診斷生態系概述
測試數量分析
定序平台實施效能分析
用戶採納狀況分析
基因診斷中的病人歷程分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態
相關人員生態系統分析
基因組數據分析基礎設施

第6章：創新趨勢

新型定序技術
產品創新分析
利用全EXOME定序定序分析臨床試驗
基於EXOME的診斷解決方案的流程分析
AI在變異解讀的應用
基於雲端的基因組學和數據分析平台
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求
關於基因組資料隱私和安全的法規

第8章：全EXOME定序序市場：展望分析

分析：依產品/服務類別
分析：按技術平台
分析：透過臨床應用
分析：按最終使用者環境
分析：依工作流程定序
分析：依樣本類型

第9章：全EXOME定序序市場：細分市場分析

按產品/服務
- 裝置
- 耗材和試劑
- 定序服務
- 生物資訊學和數據分析服務
透過技術
- 短讀定序
- 長讀長定定序
透過使用
- 臨床診斷
- 出於研究目的
最終用戶
- 醫院/診斷檢查室
- 學術研究機構
- 製藥和生物技術公司

第10章：全EXOME定序序市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：全EXOME定序序市場：國家分析

美國
加拿大
德國
英國
法國
義大利
西班牙
中國
日本
韓國
印度
澳洲
巴西
沙烏地阿拉伯
阿拉伯聯合大公國

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布
競爭標竿分析

第13章：公司簡介

Illumina, Inc.
Thermo Fisher Scientific Inc.
QIAGEN NV
F. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
Pacific Biosciences of California, Inc.
Oxford Nanopore Technologies plc
GeneDx Holdings Corp.
Revvity, Inc.
BGI Genomics Co., Ltd.
SOPHiA GENETICS SA
Fabric Genomics, Inc.
Bio-Rad Laboratories, Inc.
Centogene NV
Ambry Genetics

第14章：全EXOME定序序市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資
對基因組學基礎設施的投資
策略性資金籌措活動

第16章：未來展望

主要成長機遇
未來產業趨勢
全EXOME定序在臨床應用的發展趨勢
罕見疾病診斷的未來
人工智慧驅動的變異解讀對市場成長的影響
長期市場展望（2035 年）

簡介目錄

Product Code: KSI-009009

The whole exome sequencing market is growing at a CAGR of 9.9% from USD 3.83 billion in 2026 to USD 8.96 billion in 2035.

Whole exome sequencing (WES) analyzes the protein-coding regions of the human genome, representing approximately 1-2% of the genome while capturing the majority of known disease-causing variants. Compared with whole genome sequencing, WES offers a cost-effective and clinically relevant approach for identifying pathogenic mutations associated with inherited disorders, cancer, reproductive health, and pharmacogenomics. Continuous improvements in next-generation sequencing (NGS), long-read sequencing, artificial intelligence (AI)-driven variant interpretation, cloud-based bioinformatics, and automated laboratory workflows are expanding the role of WES in both clinical diagnostics and biomedical research.

Market Drivers

Growing Adoption of Precision Medicine

Healthcare systems increasingly rely on genomic information to personalize diagnosis and treatment. Whole exome sequencing enables clinicians to identify clinically actionable genetic variants that support individualized therapeutic decisions across multiple disease areas.

Expansion of Rare Disease Diagnostics

Rare disease programs continue to drive WES adoption because conventional diagnostic approaches frequently fail to identify underlying genetic causes. Whole exome sequencing significantly improves diagnostic yield by detecting disease-causing mutations across thousands of clinically relevant genes simultaneously.

Rising Oncology Profiling Demand

Cancer management increasingly depends on comprehensive molecular characterization. Whole exome sequencing helps identify somatic mutations, therapeutic biomarkers, resistance mechanisms, and molecular targets that support precision oncology and targeted therapies.

National Genomics Initiatives

Governments worldwide continue investing in genomic medicine programs and sequencing infrastructure to improve population health, accelerate research, and expand precision medicine implementation. These initiatives are increasing adoption of whole exome sequencing across healthcare systems.

Market Restraints

High Cost of Sequencing Infrastructure

Although sequencing costs continue to decline, laboratories still require significant investment in sequencing instruments, computational infrastructure, and specialized personnel.

Complex Variant Interpretation

Clinical interpretation of genomic variants remains challenging because many detected mutations require extensive bioinformatics analysis, clinical validation, and expert review before they can support patient management.

Regulatory and Data Privacy Challenges

Healthcare organizations must comply with evolving regulatory frameworks governing genomic testing, patient privacy, laboratory accreditation, and secure genomic data management.

Market and Technology Insights

The global whole exome sequencing market can be segmented by product & service, technology, application, end user, and geography.

By product & service, the market includes:

Instruments
Consumables & Reagents
Sequencing Services
Bioinformatics & Data Analysis Services

Consumables and reagents account for a significant market share because they are required for every sequencing workflow, while bioinformatics services continue expanding with increasing sequencing volumes.

By technology, the market comprises:

Short-Read Sequencing
Long-Read Sequencing

Short-read sequencing remains the dominant technology because of its established clinical use, while long-read sequencing is gaining momentum by improving structural variant detection and complex genomic analysis.

By application, the market includes:

Clinical Diagnostics
Research Applications

Clinical diagnostics represent an increasingly important segment as healthcare providers integrate WES into rare disease diagnosis, oncology, reproductive medicine, and precision medicine programs.

By end user, the market serves:

Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies

Hospitals and diagnostic laboratories continue expanding sequencing capabilities, while pharmaceutical companies increasingly utilize WES for biomarker discovery, drug development, and clinical trial stratification.

Market Trends

The whole exome sequencing market continues evolving through technological innovation.

Key trends include:

Expansion of AI-driven variant interpretation.
Increasing adoption of cloud-based genomics platforms.
Growing clinical implementation of WES.
Rising utilization in precision oncology.
Expansion of rare disease genomic programs.
Development of automated sequencing workflows.
Integration of genomic reporting into clinical decision support systems.

Regional Insights

North America remains the largest whole exome sequencing market because of advanced genomic medicine infrastructure, strong healthcare spending, favorable reimbursement, and significant investment in precision medicine initiatives. Academic medical centers and commercial laboratories continue expanding clinical sequencing services.

Europe maintains substantial market growth through national genomics strategies, expanding molecular diagnostics programs, and increasing collaboration between research institutions and healthcare providers.

Asia-Pacific is expected to experience the fastest growth owing to expanding biotechnology industries, improving healthcare infrastructure, increasing government support for genomic medicine, and rising adoption of next-generation sequencing technologies. China, Japan, South Korea, India, and Australia are major contributors to regional growth.

Latin America and the Middle East & Africa continue strengthening genomic capabilities through healthcare modernization, research partnerships, and increasing investment in molecular diagnostics.

Competitive Landscape

The market is characterized by continuous innovation in sequencing platforms, bioinformatics, automation, and clinical genomic interpretation.

Major companies include Illumina Inc., Thermo Fisher Scientific, QIAGEN, Roche, Agilent Technologies, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, BGI Genomics, GeneDx, Eurofins Scientific, Fulgent Genetics, and SOPHiA GENETICS. Companies continue investing in AI-powered genomic analysis, automated workflows, expanded sequencing services, and strategic collaborations to strengthen their competitive positions.

Future Outlook

The future of the whole exome sequencing market will be driven by continued expansion of precision medicine, increasing clinical adoption of genomic diagnostics, improvements in sequencing technologies, and advances in AI-enabled variant interpretation. As healthcare providers increasingly rely on genomic evidence to guide diagnosis and treatment, whole exome sequencing is expected to become a foundational component of routine clinical care across oncology, rare diseases, reproductive health, and pharmacogenomics.

Conclusion

The Global Whole Exome Sequencing Market is expected to witness strong growth through 2035, supported by increasing demand for precision medicine, expanding rare disease diagnostics, growing oncology applications, and continuous innovation in sequencing technologies. Although challenges related to implementation costs, bioinformatics complexity, and regulatory compliance remain, advances in sequencing platforms, cloud computing, and AI-driven genomic analysis are expected to create significant opportunities for diagnostic laboratories, healthcare providers, biotechnology companies, researchers, and investors.

Key Benefits of this Report

Comprehensive assessment of the global whole exome sequencing market.
Detailed evaluation of technologies, clinical applications, and emerging trends.
Analysis of competitive strategies, technological innovation, and commercialization opportunities.
Insights into precision medicine, rare disease diagnostics, oncology, and AI-powered genomic analysis.
Valuable resource for sequencing technology providers, healthcare organizations, biotechnology companies, researchers, investors, and policymakers.

What Businesses Use Our Reports For

Market opportunity assessment, product portfolio planning, competitive benchmarking, precision medicine strategy, biomarker discovery, clinical diagnostics expansion, partnership evaluation, commercialization planning, investment analysis, regulatory planning, and long-term business decision-making.

Report Coverage

Historical data from 2021 to 2025, Base Year 2026, and Forecast Period 2026 to 2035
Comprehensive analysis of the global whole exome sequencing market by Product & Service, Technology, Application, End User, and Geography
Evaluation of market dynamics, technological innovation, competitive landscape, regulatory environment, and future growth opportunities
Assessment of short-read sequencing, long-read sequencing, clinical diagnostics, research applications, AI-driven variant interpretation, cloud-based genomics, and bioinformatics platforms
Analysis of instruments, consumables & reagents, sequencing services, bioinformatics & data analysis services, hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and emerging whole exome sequencing technologies through 2035.

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Whole Exome Sequencing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Clinical Utility of Whole Exome Sequencing
3.8 Evolution of Exome-Based Genomic Testing
3.9 Genomic Diagnostics Ecosystem Overview
3.10 Testing Volume Analysis
3.11 Installed Base Analysis of Sequencing Platforms
3.12 User Adoption Analysis
3.13 Patient Journey Analysis in Genetic Diagnostics

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape
5.4 Stakeholder Ecosystem Analysis
5.5 Genomic Data Analysis Infrastructure

6. Innovation Landscape

6.1 Emerging Sequencing Technologies
6.2 Product Innovation Analysis
6.3 Clinical Trial Analysis Utilizing Whole Exome Sequencing
6.4 Pipeline Analysis of Exome-Based Diagnostic Solutions
6.5 AI Integration in Variant Interpretation
6.6 Cloud-Based Genomics and Data Analytics Platforms
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements
7.4 Genomic Data Privacy and Security Regulations

8. Whole Exome Sequencing Market Landscape Analysis

8.1 Analysis by Product & Service Category
8.2 Analysis by Technology Platform
8.3 Analysis by Clinical Application
8.4 Analysis by End User Environment
8.5 Analysis by Sequencing Workflow
8.6 Analysis by Sample Type

9. Whole Exome Sequencing Market Segment Analysis (2021-2035)

9.1 By Product & Service
- 9.1.1 Instruments
- 9.1.2 Consumables & Reagents
- 9.1.3 Sequencing Services
- 9.1.4 Bioinformatics & Data Analysis Services
9.2 By Technology
- 9.2.1 Short-Read Sequencing
- 9.2.2 Long-Read Sequencing
9.3 By Application
- 9.3.1 Clinical Diagnostics
- 9.3.2 Research Applications
9.4 By End User
- 9.4.1 Hospitals & Diagnostic Laboratories
- 9.4.2 Academic & Research Institutes
- 9.4.3 Pharmaceutical & Biotechnology Companies